

NCT00108745 GOG-0212 D1 Clinical NCTN/NCORP Data Archive

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

J Clin Oncol. 2022 Dec 10;40(35):4119-4128  
doi: 10.1200/JCO.22.00146  
Epub 2022 Jun 27  
PMID: 35759733; PMCID: PMC9746779  
Data as of: February 26, 2019

NCT00108745-D1: This dataset contains the data from the treatment comparison between 12 Monthly Cycles of single agent paclitaxel or CT-2103(IND# 70177) versus no treatment in trial NCT00108745. NCT00108745-D2 contains QOL data, NCT00108745-D3 contains maximum grade of adverse event data by system organ class and NCT00108745-D4 contains maximum grade of adverse events data by preferred terms.

These Data can be used to approximate the published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g. when data must be modified for de-identification purposes or have undergone further data cleaning).

Seq	Name	Type	Definition
1	upi	char	Universal Patient ID

Seq	Name	Type	Definition
2	rx	char	Randomized Treatment

Code
CT-2103
Paclitaxel
Surveillance

Seq	Name	Type	Definition
3	codth	char	Cause of Death

Code
Cancer
Other
Unknown
Alive

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
4	site	char	Site of Disease

<i>Code</i>
Ovary
Fallopian tube
Peritoneum

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
5	survstat	char	Survival Status

<i>Code</i>
Alive at last contact
Dead

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
6	survtime	num	Months at risk of death

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
7	pfstat	char	Status of progression-free survival

<i>Code</i>
Alive and progression-free
Progressed or died

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
------------	-------------	-------------	-------------------

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
8	pfstime	num	Months at risk of progression or death

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
9	racecat	char	Race

<i>Code</i>
Black/African American
White
Asian
Am Indian/Alaskan
N Hawaiian/Pacific Is.
Other/unspecified

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
10	ethncat	char	Ethnicity

<i>Code</i>
Hispanic
Non-Hispanic
Other/Unspecified

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
11	agecat	char	Age Group (years)

<i>Code</i>
<40
40-49
50-59
60-69

<i>Code</i>
70-79
>=80

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
12	stg	char	Stage

<i>Code</i>
III
IV

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
13	ct	char	Histology/Grade

<i>Code</i>
Serous/Grade 1
Serous/Grade 2
Serous/Grade 3
Endometrioid adenoca.
Clear Cell Carcinoma
Mucinous Adenoca.
Other/Not specified

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
14	resid	char	Residual Disease Status

<i>Code</i>
No
Yes

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
15	ca125cat	char	Initial CA125 category

<i>Code</i>
<= 10 IU
> 10 IU

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
16	init_rx	char	Initiated Study Treatment

<i>Code</i>
No
Yes

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
17	rxpp	char	Initiated anti-cancer treatment before documented progression

<i>Code</i>
No
Yes

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
18	elig	char	Met eligibility criteria

<i>Code</i>
No
Yes

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
19	flost	char	Lost to follow-up

Code
No
Yes

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
20	neuroff	char	Neurotoxicity contributed to reason for stopping treatment

Code
No
Yes

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
21	neuropathy_sensory	char	Max Grade of Sensory Neuropathy

Code
No AE reported
1
2
3
4

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
22	fatigue	char	Max Grade of Fatigue

<i>Code</i>
No AE reported
1
2
3

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
23	neutrophils	char	Max Grade of Decreased Neutrophils

<i>Code</i>
No AE reported
1
2
3
4

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
24	hair_loss_alop ecia_scalp_or_ bod	char	Max Grade of Hair loss/Alopecia

<i>Code</i>
No AE reported
1
2

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
25	pain_bone	char	Max Grade of Bone pain

<i>Code</i>
-------------

<i>Code</i>
No AE reported
1
2
3

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
26	pain_muscle	char	Max Grade of Muscle Pain

<i>Code</i>
No AE reported
1
2
3

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
27	hypokalemia	char	Max Grade of Hypokalemia

<i>Code</i>
No AE reported
1
3